Common Equity (Quarterly)

Common Equity: The sum of all common equity items.

ANI Pharmaceuticals, Inc. (ANIP) had Common Equity of $451.96M for the most recently reported fiscal quarter, ending 2024-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2024-03-31

Income Statement Financials
Revenue	$137.43M
Net Income	$17.80M
Cost of Goods Sold	$49.16M
Gross Profit	$88.27M
Operating Expenses	$117.12M
Operating Income	$20.31M
Non-Operating Income/Expense	$5.02M
Pre-Tax Income	$25.34M
Normalized Pre-Tax Income	$25.34M
Income after Taxes	$18.21M
Income from Continuous Operations	$18.21M
Consolidated Net Income/Loss	$18.21M
Normalized Income after Taxes	$18.21M
EBIT	$20.31M
EBITDA	$35.00M
Weighted-Average Shares Outstanding (Basic)	19.10M
Weighted-Average Shares Outstanding (Diluted)	19.42M
Earnings per Share (EPS) (Basic)	$0.84
Earnings per Share (EPS) (Diluted)	$0.82
Balance Sheet Financials
Current Assets	$540.56M
Property, Plant, and Equipment	$48.53M
Long-Term Assets	$373.97M
Total Assets	$914.52M
Current Liabilities	$136.89M
Long-Term Debt	$284.61M
Long-Term Liabilities	$300.82M
Total Liabilities	$437.71M
Common Equity	$451.96M
Tangible Shareholders Equity	$252.55M
Shareholders Equity	$476.81M
Common Shares Outstanding	20.99M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$18.27M
Cash Flow from Investing Activities	$8.93M
Cash Flow from Financial Activities	$-19.73M
Beginning Cash	$221.12M
End Cash	$228.60M
Increase/Decrease in Cash	$7.48M
Stock-Based Compensation	$6.93M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$-0.41M
Fundamental Metrics & Ratios
Current Ratio	3.95
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.37
Debt to Equity Ratio	0.60
Gross Margin	64.23%
Operating Margin	14.78%
EBIT Margin	14.78%
EBITDA Margin	--
Pre-Tax Profit Margin	18.43%
Profit Margin	12.95%
Free Cash Flow	$27.20M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.43
Receiveable Turnover	0.80
Days Sales in Receivables	112.91
Return on Equity	4.03%
Return on Tangible Equity	7.21%
Return on Assets	1.99%
Return on Investments	2.39%
Book Value Per Share	$22.71
Free Cash Flow per Share	$1.40
Operating Cash Flow per Share	$0.94

Data from Zacks Investment Research, Inc.